Blood biomarkers with Parkinson’s disease clusters and prognosis: the Oxford Discovery cohort by Lawton, Michael A et al.
                          Lawton, M. A., Baig, F., Toulson, G., Morovat, A., Evetts, S. G., Ben-
Shlomo, Y., & Hu, M. (2019). Blood biomarkers with Parkinson’s disease
clusters and prognosis: the Oxford Discovery cohort. Movement Disorders.
https://doi.org/10.1002/mds.27888
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1002/mds.27888
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://onlinelibrary.wiley.com/doi/10.1002/mds.27888 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
R E S E A R C H A R T I C L E
Blood Biomarkers With Parkinson’s Disease Clusters and Prognosis:
the Oxford Discovery Cohort
Michael Lawton, BSc, MPhil, MSc,1* Fahd Baig, DPhil,2,3 Greg Toulson, PhD, MSc,4 Alireza Morovat, PhD, FRCPath,4
Samuel G. Evetts, MSc,2,3 Yoav Ben-Shlomo, PhD, MSc,1 and Michele T. Hu, PhD, FRCP2,3,5
1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
2Nufﬁeld Department of Clinical Neurosciences, Division of Clinical Neurology, University of Oxford, Oxford, UK
3Oxford Parkinson’s Disease Centre, University of Oxford, Oxford, UK
4Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
5Department of Clinical Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
ABSTRACT: Background: Predicting prognosis in
Parkinson’s disease (PD) has important implications for
individual prognostication and clinical trials design and
targeting novel treatments. Blood biomarkers could help
in this endeavor.
Methods: We identiﬁed 4 blood biomarkers that might
predict prognosis: apolipoprotein A1, C-reactive pro-
tein, uric acid and vitamin D. These biomarkers were
measured in baseline serum from 624 Parkinson’s dis-
ease subjects (median disease duration, 1.0 years;
interquartile range, 0.5–2.0) from the Oxford Discovery
prospective cohort. We compared these biomarkers
against PD subtypes derived from clinical features in
the baseline cohort using data-driven approaches. We
used multilevel models with MDS-UPDRS parts I, II,
and III and Montreal Cognitive Assessment as out-
comes to test whether the biomarkers predicted subse-
quent progression in motor and nonmotor domains. We
compared the biomarkers against age of PD onset and
age at diagnosis. The q value, a false-discovery rate
alternative to P values, was calculated as an adjust-
ment for multiple comparisons.
Results: Apolipoprotein A1 and C-reactive protein levels
differed across our PD subtypes, with severe motor disease
phenotype, poor psychological well-being, and poor sleep
subtype having reduced apolipoprotein A1 and higher C-
reactive protein levels. Reduced apolipoprotein A1, higher
C-reactive protein, and reduced vitamin D were associated
with worse baseline activities of daily living (MDS-UPDRS II).
Conclusion: Baseline clinical subtyping identiﬁed a pro-
inﬂammatory biomarker proﬁle signiﬁcantly associated with
a severe motor/nonmotor disease phenotype, lending bio-
logical validity to subtyping approaches. No blood bio-
marker predicted motor or nonmotor prognosis. © 2019
The Authors.Movement Disorders published by Wiley Peri-
odicals, Inc. on behalf of International Parkinson and Move-
ment Disorder Society.
Key Words: Parkinson’s disease; cohort studies; prog-
nosis; blood biomarkers
Introduction
Parkinson’s disease (PD) is a heterogeneous multisystem
neurodegenerative disorder displaying marked variation in
phenotype and individual prognosis. There is a critical need
for biomarkers to predict both motor and nonmotor out-
comes to guide research into disease mechanisms, maximize
power in clinical trials, and delineate subtypes. The ultimate
aim would be to use this information to identify patients at
risk of early deterioration for treatment with drugs aimed at
slowing or halting the disease process. In clinical practice,
this would have signiﬁcant implications for the individual
(personalized treatment and future planning), as well as
directing health and social service resource use.
A blood-based biomarker, particularly if commercially
available, would confer a number of advantages including
ease of sample collection, cost, and scalability. We selected
4 potential blood-based biomarkers based on expert opinion
and contemporary evidence1,2: vitamin D, apolipoprotein
A1 (ApoA1), uric acid, andC-reactive protein (CRP).
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly
cited.
*Correspondence to: Mr. Michael Lawton, Ofﬁce G.04, Canynge Hall,
39 Whatley Road, Bristol. BS8 2PS. UK; michael.lawton@bristol.ac.uk
Received: 26 February 2019; Revised: 3 September 2019; Accepted:
18 September 2019
Published online 00 Month 2019 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.27888
Movement Disorders, 2019 1
There is high-quality and reproducible evidence that
vitamin D is lower in PD cases compared with controls.3-5
The mechanisms underpinning this association are not
clear, but evidence for a causal role comes from preclini-
cal studies showing a neuroprotective effect in animal
models6 and the potential association of vitamin D
receptor (VDR) polymorphisms with PD, although the
studies to date have been inconsistent.7-9
Higher levels of ApoA1 may confer some form of
neuroprotection. This was identiﬁed as a protein of
interest by a screening method for candidate plasma
proteins in a cohort study, and lower levels of ApoA1
were associated with an earlier age at PD onset.10 They
also reported lower ApoA1 correlating with dopamine
transporter (DAT) deﬁcit using an enriched cohort of
people at high risk of developing PD.10 Mechanisms by
which circulating ApoA1 levels may affect progression
are speculative but may include an immunomodulatory
effect11 or even its effect on cardiovascular or cerebro-
vascular risk.12-14
Lower uric acid levels have been linked with a higher
risk of developing PD in large prospective incidence
studies,15-19 with lower levels associated with worsen-
ing disease severity20 and a greater rate of decline.21-23
The evidence for uric acid being neuroprotective could
relate to the role of uric acid as an antioxidant and
free-radical scavenger, which may reduce the oxidative
stress causing dopaminergic loss in PD.24,25
Evidence for the role of the inﬂammation in PD is
underpinned by postmortem studies,25-27 animal models,28
and positron emission topography imaging in vivo.29 A
proposedmechanism bywhich this pathwaymay accelerate
neurodegeneration is that once the microglia are primed,
theymay subsequently have an exaggerated response to sys-
temic inﬂammation, increasing neuronal damage.30
More recent evidence also suggests that CRP along-
side other markers of a proinﬂammatory state might
predict prognosis in incident PD.31
The use of a large early-PD cohort of well-characterized
patients in a longitudinal study, such as the Oxford Dis-
covery cohort, would allow rigorous external evaluation
of these baseline biomarkers as well as testing for support-
ive evidence of biological validity to underpin the
Parkinson’s clinical subtypes we have previously reported
in more than 2500 early-PD patients recruited from the
Oxford Discovery and Tracking Parkinson’s longitudinal
cohorts,32,33
Materials and Methods
Patient Selection With Inclusion/Exclusion
Criteria
PD patients diagnosed within the past 3.5 years were
prospectively recruited as part of the Oxford Parkinson’s
Disease Centre Discovery cohort study from 11 hospitals
across the Thames Valley covering a population of approx-
imately 2.1 million (PD-Discovery website: http://opdc.
medsci.ox.ac.uk). Full details of this cohort are described
elsewhere,34 with participants recruited between September
2010 and January 2015. We only included individuals in
this study if they had a probability of PD ≥ 90% as rated
by a research neurologist/movement disorder specialist at
the latest longitudinal follow-up visit. Patients were
followed up in clinic every 18 months. Some patients who
found it too difﬁcult to attend clinic converted to telephone
follow-up, still every 18 months.
Patient Evaluation
Assessments of patients was via self-completed ques-
tionnaires and from outpatient clinics using standardized
and validated scales both at baseline and follow-up. For
this article we focused on 4 outcome measures: motor
function as measured by the Movement Disorders Soci-
ety (MDS) revised Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS) part III, activities of daily living as mea-
sured by the MDS-UPDRS part II, nonmotor aspects as
measured by the MDS-UPDRS part I, and cognition as
measured by the Montreal Cognitive Assessment
(MoCA) adjusted for education years. Only MDS-
UPDRS parts I and II were available for those patients
who converted to telephone follow-up.
We also used data-derived PD subtypes from a range of
motor, nonmotor, and cognitive symptoms at baseline.
These clusters were calculated using a factor analysis
followed by a k-means cluster analysis considering 2 to
5 clusters. In our ﬁrst article on this subject we used only the
Discovery cohort (n = 769) and decided that 5 clusters gave
us the optimal solution.32 In our second article on this sub-
ject we used 2 cohorts, with the Tracking Parkinson’s cohort
(n = 1601) chosen to be the development cohort (as it was
larger) and the Discovery cohort (n = 944) chosen to be the
validation cohort.33 In this article we decided that 4 clusters
gave us the optimal solution. Comparing the actual and
predicted clusters in Discovery gave us a kappa statistic of
0.58, indicatingmoderate agreement and providing evidence
our cluster approach was stable across the 2 cohorts. These
4 clusters were shown to be associated with subsequent
motor progression over an average of 3 years and also with
medication response using a levodopa challenge. The identi-
ﬁed clusters were named (1) fast motor progression with
symmetrical motor disease, poor olfaction, cognition, and
postural hypotension; (2) mild motor and nonmotor disease
with intermediate motor progression; (3) severe motor dis-
ease, poor psychological well-being, and poor sleep with an
intermediate motor progression; and (4) slow motor pro-
gression with tremor-dominant, unilateral disease. In this
article we compare our biomarkers against the 4 clusters
from our development/validation article.33
The laboratory assays were carried out by the use of
Abbott reagents on their autoanalysers (Abbott Diagnostics,
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Chicago, IL) according to the manufacturer’s instructions.
Serum CRP and ApoA1 were measured using immu-
notubidometric assays on an Architect C16000, as
described in kit inserts 8G65-21 30-4143/R1 and 9D92-21
3-4624/R02, respectively. Serum uric acid was measured
using a linked enzymatic assay, also on an Architect
C16000, as described in kit insert 3P39 304647/R02. Serum
25(OH)-VitD was measured using a 1-step immunoassay
on an Architect i2000, as described in kit insert 3L52
49-8941/R02.
For more in-depth details of how we used a patient’s
baseline serum to measure the 4 blood biomarkers, see
the web appendix.
Standard Protocol Approvals, Registrations,
and Patient Consents
The study was undertaken with the understanding
and written informed consent of each subject, with the
approval of the local National Health Service ethics
committee, and in compliance with national legislation
and the Declaration of Helsinki.
Statistical Analysis
We decided that we would normalize all our bio-
markers, which would allow someone to more easily
compare one biomarker against another. After any trans-
formation we tested for normality using a Kolmogorov-
Smirnov (KS) test, for which a signiﬁcant P value would
show departure from a normal distribution.
We compared these biomarkers against our data-
derived clinical clusters using multinomial logistic regres-
sion models (with the clusters as the outcome) adjusted
for age, sex, and disease duration from diagnosis.
Our 4 prognostic outcomes of interest (MDS-UPDRS
parts I, II, and III and MoCA) were modeled longitudi-
nally using multilevel (random slope and intercept)
models in which the time axis was time since diagnosis
in years. We adjusted all our longitudinal models for age
at diagnosis and sex, which were associated with both
intercept (baseline value) and slope (rate of change); see
web Figure 1 for guide to interpretation. As a sensitivity
analysis we used pattern-mixture models that adjust for
those dropping out of the study, as we were concerned
that dropout could bias our estimates.35 Also as a sensi-
tivity analysis we imputed missing data using the mean
score of the answered questions if 80% or more of the
questions were answered in the 4 outcomes. We carried
out another sensitivity analysis in which we adjusted
MDS-UPDRS parts II and III for the levodopa-equivalent
daily dose. Precise details of how we did this are in the
web appendix. Finally, we compared these biomarkers
against age at diagnosis and age at onset using regression
models adjusted for sex and disease duration.
We used a false discovery rate (FDR) method,36 often
called the Benjamini-Hochberg method, to control for
multiple comparisons. This method is not quite as strict
as the more common familywise error rate Bonferroni
correction. We derived q values when we hoped to ﬁnd
a q < 0.05, if that was our signiﬁcance threshold.
Because these q values do not have a direct probabilistic
interpretation like P values, it is only important
whether they reach the signiﬁcance threshold. An FDR
of 5% using q values would mean that 5% of results
called signiﬁcant are false-positives. We considered the
clinical cluster, age, and each prognosis analysis to be
completely separate analyses when implementing this
method, so only 4 P values are entered into this method
at a time. As well as reporting the q values, we still
report the raw P values so that if someone disagrees
with our method they could implement their own.
Computing
All our analyses were carried out in STATA 15 except
the pattern-mixture models, which were computed in
MPlus 8.
Results
A total of 624 PD patients had their baseline serum
analyzed (see web Fig. 2 to see how we arrived at that
number). The cohort was mostly male (65%), with an
average age at diagnosis of 66 years (Table 1). At base-
line the median disease duration from diagnosis was
1.0 years, and the median levodopa-equivalent daily
dose (LEDD) at baseline was 300 mg. Only 11.9% of
patients were untreated at baseline, 56.4% were on
levodopa, and 29.5% were on a dopamine agonist.
The average follow-up time for clinic visits was 3.2
 1.9 years, and when including telephone visits it was
TABLE 1. Baseline demographics of the 624 PD patients
Variable Mean (SD); median (IQR) or n (%)
Sex (female) 219 (35.1%)
Age (years) 67.6 (10.0); 69.1 (61.1 to 74.9)
Age at diagnosis (years) 66.3 (10.1); 67.7 (59.6 to 73.8)
Disease duration from diagnosis (years) 1.3 (0.96); 1.0 (0.5 to 2.0)
LEDD total (mg) 288 (212); 300 (100 to 400)
Untreated 74 (11.9%)
Levodopa use 352 (56.4%)
Dopamine agonist use 184 (29.5%)
MDS-UPDRS III 26.3 (11.3); 25 (18 to 34)
MoCA 24.7 (3.4); 25 (23 to 27)
MDS-UPDRS II 8.8 (6.2); 8 (4 to 12)
MDS-UPDRS I 8.9 (5.3); 8 (5 to 12)
ApoA1 (g/L) 1.6 (0.3); 1.6 (1.4 to 1.8)
CRP (mg/L) 2.9 (7.1); 1.3 (0.6 to 2.5)
Uric acid (umol/L) 307 (76); 307 (253 to 358)
Vitamin D (nmol/L) 49.1 (25.0); 46 (31.1 to 62.5)
LEDD, levodopa-equivalent daily dose; MDS-UPDRS, Movement Disorder
Society Uniﬁed Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive
Assessment; ApoA1, apolipoprotein A1; CRP, C-reactive protein.
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3.5 years. Web Table 1 shows the proportion with data
at each follow-up visit (a maximum of 5 visits), the
number withdrawn at each point, and the amount of
outcome data we had available at each visit. The num-
ber of individuals withdrawing from our study is con-
sistent with other longitudinal studies at 10%–12%
(depending on whether it is clinic or telephone follow-
up) withdrawing after the baseline visit and 31%–36%
having withdrawn by visit 5 after 6 years of follow-up.
Normalizing Blood Biomarker Data
ApoA1 level looked normally distributed, so it was
just standardized to unit standard deviation
(KS P = 0.66). For CRP we ﬁrst log-transformed the vari-
able and then standardized it to unit standard deviation
(KS P = 0.20), similar to a previous study.37 Uric acid
level looked normally distributed, and because there is a
profound sex effect on uric acid, we standardized sex
(KS for men, P = 0.62; KS for women, P = 0.22). As vita-
min D varies by season, we standardized the raw data
using the methods described by Lawlor et al,38 which
involved log-transforming the variable and then
adjusting for seasonal variation using a linear regression
model with a trigonometric function (KS P = 0.10).
Biomarker Versus Data-Derived PD Subtypes
When considering our PD subtypes (clusters) against
our biomarkers (see Table 2), we found strong differ-
ences in ApoA1 (P < 0.001) and CRP (P = 0.02) levels.
In both biomarkers associations seem to be driven by
the third cluster, which was our severe motor, poor
psychological well-being, and poor sleep cluster.33 This
cluster had lower ApoA1 and higher CRP levels. These
differences remained signiﬁcant after adjusting for mul-
tiple comparisons (ApoA1, q = 0.001; CRP, q = 0.03).
TABLE 2. Biomarkers versus clusters from PD subtypes article, adjusted for age, sex, and disease duration
Blood biomarker Cluster 1 n = 210 Cluster 2 n = 104 Cluster 3 n = 152 Cluster 4 n = 155 Adjusted P value q value
ApoA1 (g/L) 1.63 (0.24) 1.69 (0.25) 1.53 (0.22) 1.64 (0.27) < 0.001 0.001
CRP (mg/L) 2.65 (8.1) 1.93 (2.7) 4.06 (9.7) 2.6 (4.1) 0.02 0.03
Uric acida (umol/L) 306 (75) 292 (67) 323 (77) 304 (81) 0.22 0.30
Vitamin D (nmol/L) 48.0 (22) 51.4 (27) 46.8 (28) 50.6 (24) 0.38 0.38
ApoA1, apolipoprotein A1; CRP, C-reactive protein.
aUric acid was standardised by sex so the adjusted associations are not adjusted with a sex term in the model.
TABLE 3. Longitudinal follow-up associations (per standard deviation change in transformed biomarker)
Adjusted associations
MDS-UPDRS III Intercept Slope (per year) Intercept q value Slope q value
ApoA1 −0.90 (−2.06 to 0.25); 0.12 −0.06 (−0.40 to 0.29); 0.74 0.17 0.91
CRP −0.35 (−1.39 to 0.69); 0.51 0.26 (−0.05 to 0.57); 0.09 0.51 0.19
Uric acida −0.96 (−2.02 to 0.10); 0.08 0.36 (0.04 to 0.68); 0.03 0.17 0.11
Vitamin D −0.82 (−1.87 to 0.24); 0.13 0.02 (−0.29 to 0.33); 0.91 0.17 0.91
MoCA Adjusted associations
Intercept Slope (per year) Intercept q value Slope q value
ApoA1 0.29 (−0.02 to 0.60); 0.07 0.00 (−0.08 to 0.08); 0.99 0.24 0.99
CRP −0.19 (−0.48 to 0.09); 0.18 −0.02 (−0.10 to 0.05); 0.50 0.24 0.67
Uric acida 0.21 (−0.08 to 0.50); 0.16 −0.03 (−0.10 to 0.05); 0.48 0.24 0.67
Vitamin D 0.16 (−0.13 to 0.45); 0.27 0.03 (−0.05 to 0.10); 0.48 0.27 0.67
MDS-UPDRS II Adjusted associations
Intercept Slope (per year) Intercept q value Slope q value
ApoA1 −0.93 (−1.50 to −0.35); 0.002 −0.07 (−0.21 to 0.07); 0.34 0.004 0.45
CRP 0.81 (0.29 to 1.34); 0.002 0.11 (−0.03 to 0.24); 0.12 0.004 0.29
Uric acida 0.04 (−0.49 to 0.57); 0.88 0.04 (−0.09 to 0.18); 0.53 0.88 0.53
Vitamin D −0.75 (−1.28 to −0.22); 0.005 −0.10 (−0.23 to 0.03); 0.14 0.007 0.29
MDS-UPDRS I Adjusted Associations
Intercept Slope (per year) Intercept q value Slope q value
ApoA1 −0.82 (−1.31 to −0.33); <0.001 −0.02 (−0.13 to 0.09); 0.76 0.004 0.76
CRP 0.45 (0.01 to 0.90); 0.047 0.06 (−0.04 to 0.17); 0.22 0.06 0.61
Uric acida 0.53 (0.08 to 0.99); 0.02 −0.05 (−0.16 to 0.05); 0.31 0.04 0.61
Vitamin D −0.41 (−0.86 to 0.05); 0.08 −0.03 (−0.13 to 0.07); 0.56 0.08 0.75
MDS-UPDRS, Movement Disorder Society Uniﬁed Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; ApoA1, apolipoprotein A1; CRP,
C-reactive protein.
Data (except where stated) are estimate (95% conﬁdence interval); P value. Models are adjusted for age at diagnosis and sex.
aUric acid was standardized by sex so the adjusted associations are not adjusted with a sex term in the model.
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Longitudinal Analysis
Motor predictors
The adjusted results from our main analysis are in
Table 3, whereas the crude results are in web Table 2.
There was a modest association between uric acid and
MDS-UPDRS III (P = 0.03), with a 1 standard devia-
tion increase associated with a 0.36 increase in MDS-
UPDRS III change per year. Hence, raised uric acid was
associated with worse motor prognosis. However this
association was not signiﬁcant after adjusting for multi-
ple comparisons (q = 0.11).
Cognitive predictors
There were no strong associations between the bio-
markers with either MoCA intercept or slope.
Activities of daily living predictors
ApoA1, CRP, and vitamin D were all strongly associ-
ated with the MDS-UPDRS II intercept, both before
(P < 0.05) and after adjustment for multiple compari-
sons (q < 0.05). Hence, reduced ApoA1, raised CRP,
and reduced vitamin D were associated with worse
activities of daily functionality at baseline.
Nonmotor predictors
ApoA1, CRP, and uric acid were associated with the
MDS-UPDRS I intercept (P < 0.05). Hence, reduced
ApoA1, raised CRP and raised uric acid were associ-
ated with worse nonmotor function at baseline. ApoA1
(q = 0.004) and uric acid (q = 0.04) remained signiﬁ-
cant after adjusting for multiple comparisons; however,
CRP was no longer signiﬁcant (q = 0.06).
Sensitivity Analyses
Results from the pattern-mixture models (see Table 4),
attenuated the association between uric acid and MDS-
UPDRS III slope (P = 0.10 and q = 0.24). It also slightly
attenuated the associations between ApoA1, CRP, and vita-
min D and the MDS-UPDRS II intercept; however, they all
remained statistically signiﬁcant (P < 0.05 and q < 0.05).
The association between uric acid and the MDS-UPDRS I
intercept was attenuated to the null and no longer signiﬁ-
cant (P = 0.06 and q = 0.11). The association between
ApoA1 and the MDS-UPDRS I intercept was no longer sig-
niﬁcant after adjusting for multiple comparisons (q = 0.08).
The results from our sensitivity analysis in which we
imputed data if 80% or more of the questions were
answered (see web Table 3 for adjusted results and web
Table 4 for crude results) were similar to our main
TABLE 4. Pattern mixture model (adjusted for withdrawal) longitudinal follow-up associations (per standard deviation change
in transformed biomarker)
Adjusted associations
MDS-UPDRS III Intercept Slope (per year) Intercept q value Slope q value
ApoA1 −0.93 (−2.02 to 0.16); 0.10 0.04 (−0.30 to 0.38); 0.82 0.36 0.90
CRP −0.40 (−1.40 to 0.60); 0.43 0.26 (−0.07 to 0.58); 0.12 0.43 0.24
Uric acida −0.70 (−1.82 to 0.41); 0.22 0.29 (−0.05 to 0.64); 0.10 0.36 0.24
Vitamin D −0.65 (−1.79 to 0.50); 0.27 −0.02 (−0.38 to 0.33); 0.90 0.36 0.90
MoCA Adjusted Associations
Intercept Slope (per year) Intercept q value Slope q value
ApoA1 0.29 (−0.04 to 0.62); 0.08 −0.02 (−0.11 to 0.07); 0.64 0.23 0.72
CRP −0.17 (−0.46 to 0.12); 0.24 −0.03 (−0.12 to 0.06); 0.57 0.28 0.72
Uric acida 0.25 (−0.06 to 0.55); 0.12 −0.05 (−0.14 to 0.05); 0.32 0.23 0.72
Vitamin D 0.16 (−0.12 to 0.44); 0.28 0.02 (−0.07 to 0.10); 0.72 0.28 0.72
MDS-UPDRS II Adjusted associations
Intercept Slope (per year) Intercept q value Slope q value
ApoA1 −0.73 (−1.33 to −0.13); 0.02 −0.16 (−0.35 to 0.02); 0.08 0.02 0.32
CRP 0.76 (0.18 to 1.34); 0.01 0.11 (−0.05 to 0.27); 0.17 0.02 0.33
Uric acida 0.07 (−0.52 to 0.66); 0.82 0.06 (−0.11 to 0.24); 0.48 0.82 0.48
Vitamin D −0.74 (−1.31 to −0.17); 0.01 −0.06 (−0.23 to 0.11); 0.48 0.02 0.48
MDS-UPDRS I Adjusted associations
Intercept Slope (per year) Intercept q value Slope q value
ApoA1 −0.65 (−1.20 to −0.11); 0.02 −0.10 (−0.26 to 0.07); 0.25 0.08 0.49
CRP 0.40 (−0.10 to 0.90); 0.12 0.08 (−0.06 to 0.23); 0.24 0.12 0.49
Uric acida 0.50 (−0.01 to 1.00); 0.06 −0.03 (−0.16 to 0.10); 0.63 0.11 0.79
Vitamin D −0.44 (−0.99 to 0.11); 0.12 0.02 (−0.11 to 0.14); 0.79 0.12 0.79
MDS-UPDRS, Movement Disorder Society Uniﬁed Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; ApoA1, apolipoprotein A1; CRP,
C-reactive protein.
Data (except where stated) are estimate (95% conﬁdence interval); P value. Models are adjusted for age at diagnosis and sex.
aUric acid was standardized by sex but the adjusted associations are still adjusted with a sex term in the model because the interaction between sex and with-
drawal has residual confounding with the standardized uric acid.
Movement Disorders, 2019 5
P A R K I N S O N ’ S B I O M A R K E R P R O G N O S I S
analysis, although one could argue the association between
CRP and the MDS-UPDRS III slope was strengthened
slightly. Also, the results from our sensitivity analysis
adjusting MDS-UPDRS II and III for LEDD (see web
Table 5 for adjusted results and web Table 6 for crude
results) were similar to the main analysis.
Biomarker versus age at onset and diagnosis
Raised uric acid was associated with higher age at onset
(P = 0.02) and higher age at diagnosis (P = 0.03), see
Table 5, but were not signiﬁcant after adjustment for mul-
tiple comparisons (q = 0.09 for both age at onset and
diagnosis). There were borderline associations between
raised CRP, higher age at onset (P = 0.05), and higher age
at diagnosis (P = 0.045); however, these were not signiﬁ-
cant after adjustment for multiple comparisons (q = 0.10
and q = 0.09, respectively).
Discussion
Baseline clinical subtyping approaches identiﬁed a
proinﬂammatory biomarker proﬁle (reduced apolipopro-
tein A1 and raised CRP) signiﬁcantly associated with the
severe motor and nonmotor disease phenotype, lending
biological validity to this approach. Although after
adjustment for covariables and accounting for with-
drawal, none of our 4 blood biomarkers were associated
with prognosis (slope), but 3 of the biomarkers (ApoA1,
CRP, and vitamin D) were associated with baseline dis-
ease severity (intercept) in the case ofMDS-UPDRS II.
In this study, we found strong differences between our
biomarkers and data-derived PD subtypes derived from a
wealth of baseline phenotypic data encompassing motor,
nonmotor, and cognitive measures using a previously
published unbiased approach.32,33 These subtypes were
developed and validated in 1601 and 944 recently diag-
nosed idiopathic PD patients from the Tracking
Parkinson’s and Discovery cohorts, respectively, followed
up over a median of 3 years. The identiﬁed 4 clusters
were: (1) fast motor progression with symmetrical motor
disease, poor olfaction, cognition, and postural hypoten-
sion; (2) mild motor and nonmotor disease with interme-
diate motor progression; (3) severe motor disease, poor
psychological well-being, and poor sleep with an interme-
diate motor progression; and (4) slow motor progression
with tremor-dominant unilateral disease. The third cluster
in this study comprised 22% of the combined baseline PD
cohorts. These clusters were associated with response to
levodopa in a levodopa challenge and also with motor
progression rates.
In the current study, patients assigned to cluster
3 (severe disease group) had signiﬁcantly reduced ApoA1
and higher CRP levels compared with patients in other
clusters, suggestive of a proinﬂammatory state. This pro-
vides support to a growing consensus that both central
brain and peripheral blood immune activation are rele-
vant to PD and neurodegenerations.28,39-41 We also found
associations between reduced ApoA1 and higher CRP
levels with worse baseline MDS-UPDRS II. Reduced
ApoA1 and raised CRP have also been described in a
number of systemic conditions including colorectal carci-
noma, in which serum ApoA1 level showed a strong neg-
ative correlation with systemic markers of inﬂammation
including serum CRP and serum interleukin-8 levels. Fur-
thermore, reduced ApoA1 has predicted poor survival in
cancer40 and associations with earlier age at onset and
greater motor severity in PD.42We failed to replicate these
associations between ApoA1 with age at onset and cross-
sectional associations with UPDRS-III. The PPMI study
also failed to show an association with ApoA1 and motor
decline, albeit over a very short period of only 12 months,
which may be too short to detect differences.42 Another
incident PD cohort showed similar proinﬂammatory
response markers in the serum of incident PD subjects.31
They also found that higher CRP predicted faster rates of
change in UPDRS-III over a 3-year period, which we
failed to replicate in our own cohort.
One interesting question is why our clusters associ-
ated with motor progression rates and also with ApoA1
and CRP, but ApoA1 and CRP did not associate with
motor progression rates. This is because of our third
cluster, which drove the associations with ApoA1 and
CRP, having intermediate progression rates, whereas
cluster 1, with the fastest rate of disease progression,
did not have any association with the biomarkers.
Immune activation is described in many neurodegenera-
tive disorders including PD in the brain and peripheral
blood, leading to the hypothesis that there are common
mechanisms in these disorders through which the immune
system mediates disease initiation and/or progression.
This is of considerable interest given that the immune
TABLE 5. Biomarkers versus age at onset and age at diagnosis adjusted for sex and disease duration
Blood biomarker Direction P age at onset P age at diagnosis q Value age at onset q Value age at diagnosis
ApoA1 - 0.19 0.21 0.26 0.28
CRP + 0.05 0.045 0.10 0.09
Uric acid + 0.02 0.03 0.09 0.09
Vitamin D + 0.58 0.65 0.58 0.65
ApoA1, apolipoprotein A1; CRP, C-reactive protein.
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system is a highly tractable therapeutic target and that
therapeutic approaches targeting protein aggregation
have not yet shown efﬁcacy in clinical trials. The critical
question of whether immune changes are a primary driver
in their pathogenesis is difﬁcult to address because signiﬁ-
cant neurodegeneration has already occurred when PD
patients ﬁrst become symptomatic. Future serum analysis
work will focus on our prodromal subjects who have
polysomnographically diagnosed rapid eye movement
sleep behavior disorder (RBD) and share both nonmotor
and motor features in common with early PD.
This study adds considerable evidence to the litera-
ture on each of these analytes. Conﬂicting evidence for
the use of vitamin D and uric acid in multiple studies
has led to uncertainty over their utility to predict out-
comes in early PD, despite the precious resources used
to investigate them. Studies investigating ApoA1 and
CRP have been promising, but the same results failed
to be replicated in this large prospective cohort, and we
found no differences with progression rates in
4 domains. Therefore, this study should guide future
research toward other prognostic candidates, at least in
the short-term follow-up of 3 years.
The association we found between uric acid and MDS-
UPDRS III is interesting but also raises challenges in its
interpretation. The mounting evidence is that in
Parkinson’s disease higher uric acid levels are protective or
better.22,23 Our model seems to suggest that there is a
weak association between higher uric acid and lower
MDS-UPDRS III intercept (P = 0.08), but a slightly stron-
ger association between higher uric acid level and higher
MDS-UPDRS III slope (P = 0.03). Furthermore, looking at
the associations between uric acid and MDS-UPDRS I
intercept, these occur in the direction one would expect if
higher uric acid level predicted worse nonmotor function.
Accounting for withdrawal and multiple comparisons fur-
ther attenuated any association with progression and
intercept. It is not clear why our ﬁndings of a weak associ-
ation with uric acid level was not consistent with observa-
tional studies, suggesting an etiological protective
effect.21,43 Phase 2 intervention studies have been under-
taken showing therapeutic intervention to increase uric
acid is safe44; however, a large phase 3 trial (SURE-PD3
NCT02642393) that was expected to end in 2020 was ter-
minated early due to futility. This provides more evidence
that higher uric acid is not causally associated with better
prognosis. It should be noted that both observational stud-
ies22,23 and the Mendelian randomization study (carried
out on the same 2 populations) linking uric acid level were
based on individuals who had not been exposed to dopa-
minergic therapy, with the main outcome progression to
disability requiring dopaminergic therapy. By excluding
those who required dopaminergic therapy close to diagno-
sis, these studies might be based on individuals whose
motor symptoms were relatively mild, whereas in our
study only 11.9% remained untreated at recruitment.
It should be noted that our results provide evidence of a
cross-sectional association between serum levels and PD
disease markers. As we have not individually measured
each serum biomarker longitudinally, the directionality of
each association remains unclear, and therefore could
merely reﬂect the secondary effects of disease severity on
the serummarker. As these serum levels are associated with
baseline severity and not disease progression, they could be
a state marker of the disease rather than a trait marker of a
more malignant disease process. The proinﬂammatory
response strongly associated with cluster 3 and baseline
UPDRS-II could reﬂect a different pathophysiology driven
by neuroinﬂammation. Previous work associating CRP
with coronary heart disease severity at a cross-sectional
level was not subsequently replicated by larger Mendelian
randomization studies,37 suggesting that the results were
the effect of reverse causation or a secondary effect of dis-
ease severity.
It is intriguing to speculate that because MDS-UPDRS I
and II are patient completed, there may be some between-
individual elements like lifestyle factors that have con-
founded our associations between the biomarkers and the
MDS-UPDRS I and II intercepts. We could argue about
some P values being on the border of signiﬁcance and fur-
ther follow-up or a larger sample with increased power
might ﬁnd similar associations but with smaller conﬁ-
dence intervals. However, when examining the conﬁdence
intervals, the effect sizes all tended to be on the small side.
For instance, our signiﬁcant results between the UPDRS II
intercept and 3 of the biomarkers were at most (see 95%
conﬁdence interval of main analysis) a difference of 1.5
UPDRS II points for a change of 1 standard deviation in
the biomarker and at least a 0.2 UPDRS II points for a
change of 1 standard deviation.
Strengths, Limitations, and Conclusions
The Discovery cohort is one of the largest PD inci-
dence cohorts worldwide and currently has more than
3 years of follow-up on average. We have a wealth of
phenotypic information that went into our data-derived
PD subtypes that have been developed and validated in
2 incidence cohorts using > 2500 patients.
With more follow-up data, we will be able to consider
interesting questions about nonlinearity and complex
measurement error. Our current follow-up period may be
too short to detect different progression rates. There are
some problems with using corrections to P values,45 and
although the authors focused on statistical signiﬁcance in
the Results section, they were also aware that there are
pitfalls to this that have been highlighted before46,47
However, any adjustment we could make to our P values
for multiple testing would further justify our conclusion
that the biomarkers we tested are not related to prognosis
in any of the 4 domains we studied. For those reaching
each visit, the amount of missing data was very small, and
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our adjustments for individuals whose entire question-
naires were not completed showed similar associations
between the biomarkers and the outcomes. We also used
robust methods (pattern-mixture models) to take into
account individuals who had withdrawn from the study,
which could bias our estimates, as individuals with more
severe disease were more likely to withdraw. We also
attempted to exclude individuals who may have been mis-
classiﬁed as PD but turned out to have other parkinsonian
disorders. Our associations with vitamin D might not be
generalizable to people at different latitudes.
Our models would give a better picture of progression
had we measured the blood biomarkers at each visit
rather than just at baseline. However, the current study
design was sufﬁcient to interrogate the role of baseline
serum in inﬂuencing future progression. Further studies
should focus on longitudinal serum measurements and
on earlier disease cohorts including patients with pro-
dromal RBD sleep disorder, and carriers of monogenic
mutations strongly implicated in PD pathogenesis, such
as the glucocerebrosidase (GBA) gene. This will address
the critical question of whether immune changes are the
primary driver in PD pathogenesis or a secondary effect
of worsening disease burden.
In future work we plan to examine the genetics of our
clusters. This includes whether certain clusters are
enriched with GBA or LRRK2 carriers, whether clusters
differ in their genetic risk of developing PD, and carrying
out a genome-wide association study of belonging to a
cluster.
Last, given that therapeutic approaches targeting pro-
tein aggregation in PD have not yet shown efﬁcacy in
clinical trials, the immune system remains a highly trac-
table therapeutic target. Our data suggest that a simple,
low-cost serum-based approach could both stratify PD
patients most likely to beneﬁt from immunomodulatory
approaches and monitor future treatment response,
both of which are critically needed if we are to really
deliver neuroprotective interventions for PD.48
Acknowledgements: The authors thank all subjects who have partici-
pated in this study.
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